Drug Metabolism and Pharmacokinetics Analysis Service
Drug Metabolism and Pharmacokinetics (DMPK) analysis is a vital component of modern drug discovery and development. These studies are crucial for understanding the in vivo behavior of compounds and play a key role in optimizing drug safety, efficacy, and dosing regimens. DMPK analysis helps identify metabolic stability, potential drug-drug interaction (DDI) risks, and appropriate pharmacokinetic parameters.
MtoZ Biolabs provides professional, data-driven Drug Metabolism and Pharmacokinetics Analysis Service that support multiple stages of new drug development. By combining advanced instrument platforms with standardized experimental processes, we assist clients in reducing risks and optimizing decisions during early-phase development.
Services at MtoZ Biolabs
MtoZ Biolabs offers comprehensive Drug Metabolism and Pharmacokinetics Analysis Service that combine both in vitro and in vivo model systems to systematically evaluate the metabolism and pharmacokinetic (ADME) properties of candidate compounds. Our service includes:
1. In Vitro Biology Assay Service
MtoZ Biolabs' In Vitro Biology Assay Service provides high-throughput, cost-effective, and customizable assay platforms that accelerate the early stages of drug development. This service uses advanced technologies such as high-content imaging, flow cytometry, and ELISA to thoroughly evaluate the pharmacological activity, mechanism of action, toxicity, and biomarker responses of candidate compounds. From 2D/3D cell-based functional assays to target-based biochemical assays and phenotypic screening, MtoZ Biolabs offers experimental designs and expert support tailored to biological contexts, aiding hit validation, lead optimization, and early safety assessments. This service is widely applicable in oncology, immunology, neurology, and metabolic disease research.
MtoZ Biolabs’ In Vitro ADME Service focuses on the absorption (A), distribution (D), metabolism (M), and excretion (E) behaviors of drugs. Through a series of standardized in vitro assays that simulate physiological conditions, we help predict the in vivo performance of candidate compounds before advancing to animal models or clinical trials. Our service covers physicochemical property evaluation (solubility, lipophilicity), absorption testing (PAMPA, Caco-2, MDCK), drug distribution analysis (plasma protein binding, tissue binding, plasma distribution), in vitro metabolic stability, and metabolite identification, as well as drug-drug interaction (DDI) risk analysis (CYP inhibition, induction, and enzyme phenotyping). All experiments are coupled with high-resolution mass spectrometry and advanced biochemical platforms for data collection and analysis, ensuring reliable early-stage pharmacokinetic data to support drug screening, safety evaluations, and dosage design.
MtoZ Biolabs offers a comprehensive In Vivo DMPK Service, covering the full spectrum of in vivo ADME research. This service is available for animal models including mice, rats, and dogs, with multiple administration routes (IV, oral, subcutaneous, intraperitoneal, intramuscular). It includes assessments of systemic exposure, half-life and clearance, tissue distribution, blood-brain barrier (BBB) permeability, excretion monitoring, radioactive mass balance studies, and metabolite profiling. With our high-sensitivity LC-MS/MS platform and experienced DMPK team, MtoZ Biolabs provides high-quality, reproducible, regulatory-ready in vivo pharmacokinetic data to help clients make critical decisions during early screening and preclinical research.
Analysis Workflow
Service Advantages
1. Full Process Coverage
MtoZ Biolabs provides a complete Drug Metabolism and Pharmacokinetics Analysis Service chain from in vitro screening, ADME evaluation to in vivo pharmacokinetics research, helping clients comprehensively understand the in vivo behavior of candidate compounds.
2. Flexible Customization
We adapt our experimental design based on project goals, pharmacological targets, and compound properties. Whether for early-stage screening or regulatory submissions, we offer flexible and efficient solutions to meet the specific needs of your project.
3. Integrated Technology
Our platform integrates high-throughput and highly sensitive technologies such as ELISA, flow cytometry, high-content imaging, permeability models (Caco-2/MDCK), LC-MS/MS, and UPLC-HRMS to provide a comprehensive analysis of drug efficacy, pharmacokinetics, and toxicity. This enables efficient collection of synergistic data across multiple areas to aid in mechanism studies and drug evaluation.
4. High-Quality Data
With leading high-resolution mass spectrometry platforms (including Orbitrap and Q Exactive series), we offer precise quantification and metabolite identification in complex biological matrices. Our rigorous data processing ensures accuracy and reproducibility, making the results suitable for internal decisions, project evaluation, and regulatory submissions.
5. Professional Team
Our DMPK experts, bioanalysts, and pharmacology-toxicology specialists bring extensive experience to handle diverse compound types (small molecules, ADCs, biologics, etc.). We provide comprehensive support, from experimental design and troubleshooting to data interpretation, helping to drive efficient project progression.
Applications
1. Candidate compound screening and optimization
2. Drug systemic exposure assessment
3. Metabolic clearance mechanism research
4. Drug–drug interaction prediction
5. Oral bioavailability and absorption behavior analysis
6. Support for first-in-human dose calculations
FAQ
Q1: Can Drug Metabolism and Pharmacokinetics Analysis Service be provided as a package?
Yes, we commonly integrate metabolism, permeability, protein binding, and PK experiments, offering flexible combinations based on project requirements.
Q2: Do you support both human and animal models?
Yes, our Drug Metabolism and Pharmacokinetics Analysis Service support various models including human, mice, rats, dogs, and monkeys, with appropriate validation methods for each.
Q3: What is the typical timeline for the experiments?
In vitro experiments typically take 5–10 business days, while in vivo PK studies usually require 2–4 weeks, depending on experimental design and animal species.
Deliverables
1. Study protocol and experimental design
2. Raw data files, including chromatograms and data records
3. Processed results with pharmacokinetic parameters (Cmax, AUC, t1/2, CL, Vd)
4. Data visualization and summary of key trends
5. Comprehensive technical report with conclusions and recommendations
MtoZ Biolabs is committed to providing precise, transparent, and reliable Drug Metabolism and Pharmacokinetics Analysis Service to support your drug discovery efforts. Whether you are at the early discovery stage or preparing for regulatory submissions, our services will provide solid support for your project.
Contact us today for customized recommendations and pricing.
How to order?
